| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | sei |
| Uniprot No | A0A0H3JSY8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-242aa |
| 氨基酸序列 | MKKFKYSFILVFILLFNIKDLTYAQGDIGVGNLRNFYTKHDYIDLKGVTDKNLPIANQLEFSTGTNDLISESNNWDEISKFKGKKLDIFGIDYNGPCKSKYMYGGATLSGQYLNSARKIPINLWVNGKHKTISTDKIATNKKLVTAQEIDVKLRRYLQEEYNIYGHNNTGKGKEYGYKSKFYSGFNNGKVLFHLNNEKSFSYDLFYTGDGLPVSFLKIYEDNKIIESEKFHLDVEISYVDSN |
| 预测分子量 | 43.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SEI重组蛋白的3篇参考文献的简要总结(注：SEI蛋白可能与细菌毒素或免疫调控相关，以下内容基于学术常见方向模拟)：
1. **标题**：*Expression and purification of recombinant SEI protein from Staphylococcus aureus for immunological studies*
**作者**：Zhang, L., et al.
**摘要**：研究利用大肠杆菌系统高效表达并纯化重组SEI蛋白(葡萄球菌肠毒素I)，优化了诱导条件及纯化步骤，验证了其与T细胞受体的结合活性，为后续免疫机制研究奠定基础。
2. **标题**：*Development of a SEI-based ELISA for rapid detection of Staphylococcus aureus infections*
**作者**：Wang, Y., & Chen, H.
**摘要**：开发基于重组SEI蛋白的ELISA检测方法，用于临床样本中金黄色葡萄球菌感染的快速诊断，实验显示高灵敏度和特异性，显著优于传统培养法。
3. **标题**：*Structural and functional analysis of recombinant SEI protein in autoimmune disease models*
**作者**：Smith, J., et al.
**摘要**：通过晶体学解析重组SEI蛋白的三维结构，并在小鼠模型中证明其通过调控T细胞活性缓解类风湿关节炎症状，提示其作为免疫治疗靶点的潜力。
(注：以上文献为示例，实际研究中建议通过PubMed或Web of Science以“SEI recombinant protein”或“Staphylococcal enterotoxin I recombinant”等关键词检索最新文献。)
**Background of SEI Recombinant Protein**
SEI (Staphylococcal enterotoxin I) recombinant protein is a biologically engineered derivative of the native SEI toxin produced by *Staphylococcus aureus*. Staphylococcal enterotoxins (SEs) are a family of superantigens known for their ability to bypass normal antigen processing, directly binding to major histocompatibility complex (MHC) class II molecules on antigen-presenting cells and specific T-cell receptor (TCR) Vβ regions. This interaction triggers massive T-cell activation and cytokine release, contributing to pathologies like toxic shock syndrome and food poisoning.
Recombinant SEI is generated through cloning and expression of the *sei* gene in heterologous systems (e.g., *E. coli* or yeast), enabling scalable production with high purity. Unlike native SEI, the recombinant form is often modified to reduce toxicity while retaining immunogenic or structural properties, making it valuable for research and therapeutic applications.
In research, SEI recombinant protein serves as a tool to study superantigen-mediated immune responses, TCR-MHC interactions, and mechanisms of T-cell activation. Its controlled production allows for precise investigation of immune dysregulation and pathogenicity. Additionally, it has potential applications in immunotherapy, such as designing inhibitors to block superantigen activity or engineering attenuated variants for immune modulation.
The protein also aids in diagnostic development, including antibody-based assays to detect *S. aureus* infections. Furthermore, structural studies using recombinant SEI have provided insights into its binding domains and conformational dynamics, informing drug design and vaccine strategies.
Despite its utility, handling recombinant SEI requires caution due to residual superantigenic activity. Ongoing research focuses on optimizing its safety profile and exploring novel applications in infectious disease and cancer therapeutics. Overall, SEI recombinant protein bridges microbiological pathogenesis studies with translational innovations in immunology.
(Word count: 249)
×
